These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35456557)

  • 21. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
    Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
    Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
    Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
    Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema.
    Coney JM
    Int Med Case Rep J; 2019; 12():161-169. PubMed ID: 31213929
    [No Abstract]   [Full Text] [Related]  

  • 25. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
    Gonzalez VH; Luo C; Almeida DRP; Cutino A; Coughlin B; Kasper J; Kiernan DF; ; ;
    Retina; 2023 Aug; 43(8):1301-1307. PubMed ID: 37130434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review.
    Kodjikian L; Baillif S; Creuzot-Garcher C; Delyfer MN; Matonti F; Weber M; Mathis T
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33430389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 29. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
    Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM
    Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.
    Rosenblatt A; Udaondo P; Cunha-Vaz J; Sivaprasad S; Bandello F; Lanzetta P; Kodjikian L; Goldstein M; Habot-Wilner Z; Loewenstein A;
    Ophthalmology; 2020 Mar; 127(3):377-393. PubMed ID: 31932090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluocinolone acetonide for the treatment of diabetic macular edema.
    Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
    Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Early efficacy of dexamethasone implant (OZURDEX
    Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
    J Fr Ophtalmol; 2017 May; 40(5):408-413. PubMed ID: 28336283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study.
    Rousseau N; Lebreton O; Masse H; Maucourant Y; Pipelart V; Clement M; Le Lez ML; Khanna RK; Pepin M; Eude Y; Le Meur G; Weber M; Ducloyer JB
    Ophthalmol Ther; 2023 Oct; 12(5):2781-2792. PubMed ID: 37369907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis.
    Yuan Q; Liu Y; Gou Y; Xu H; Gao Y; Liu Y; Chen Y; Zhang M
    Front Pharmacol; 2022; 13():1029584. PubMed ID: 36532786
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
    Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
    Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in the UAE: 24 and 36-month outcomes.
    Elbarky A
    Eur J Ophthalmol; 2022 Sep; ():11206721221128671. PubMed ID: 36168254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.